Eli Lilly announced 52-week data from Phase 3b trials showing that the concomitant use of Taltz and Zepbound maintained or improved efficacy in psoriatic disease and obesity, with continued improvements in systemic inflammation and metabolic outcomes. This data reinforces the potential of this drug combination and contributes to the understanding of immunometabolic health.
Eli Lilly disclosed positive 52-week data from its TOGETHER-PsO and TOGETHER-PsA Phase 3b trials, demonstrating that the combination of Taltz and Zepbound maintained or further improved efficacy in patients with psoriatic disease and obesity. This is significant because it confirms the long-term benefits observed at 36 weeks and highlights the potential for Taltz and Zepbound to address both dermatological and metabolic aspects of these conditions. This data strengthens Eli Lilly's position in the immunology and metabolic disease markets, offering a potential competitive advantage. For traders, this reinforces the positive outlook for LLY, suggesting continued revenue growth potential from these key products, especially as the market for GLP-1s expands into new indications. The long-term implication is a broader application and market share for these drugs, while short-term impact could be a modest positive sentiment boost.